Summary:
This is a Phase 3, 6-week, randomized, double-blind, placebo-controlled, multicenter, outpatient study in subjects with schizophrenia with an inadequate response to their current atypical antipsychotic treatment.
- Subject is aged 18 to 55 years at Screening
- Subject has a primary diagnosis of schizophrenia
- Subject is currently being treated with monotherapy risperidone, paliperidone, aripiprazole, ziprasidone or lurasidone and has been taking this treatment with the same dosing regimen for at least 8 weeks at the time of Screening
- The subject has had at least 1 previous inadequate response to above antipsychotics that was dosed appropriately for at least 6 weeks
- The subject has not required psychiatric hospitalization, incarceration in prison, acute crisis intervention, or other increase in the level of care due to symptom exacerbation within 8 weeks of Screening
- Body Mass Index (BMI) must be within 18 to 40 kg/m2
Qualified Participants May Receive:
• No-cost study medication
• No-cost study-related care from a local doctor
• NCompensation